New Products

Mar 06, 2018

Baylor Genetics ClariFind

Baylor Genetics has launched ClariFind, a somatic tumor next-generation sequencing test that analyzes alterations in 277 cancer genes for both solid tumors and hematologic malignancies. The test uses molecular indexing prior to PCR and sequencing to enable the detection of low-frequency mutations. The ClariFind report provides annotated genomic findings, any associated targeted therapies and available clinical trials, and an interpretative summary.

Feb 26, 2018

Genomic Health Oncotype DX AR-V7 Nucleus Detect

Genomic Health has launched the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy assay intended to predict treatment response in men with advanced prostate cancer. Developed and performed by circulating tumor cell firm Epic Sciences, the new assay is the first of its kind to be commercially marketed. The test detects the presence of a splice variant of the androgen receptor protein in the nucleus of CTCs using Epic's detection and analysis platform.

The presence of AR-V7 has been shown in research studies to be predictive of whether men will respond to androgen receptor-signaling inhibitors like enzalutamide and abiraterone, or might be better served by chemotherapy.

Feb 22, 2018

Tempus xE Whole-Exome Tumor Sequencing

Personalized cancer technology company Tempus has introduced Tempus xE, a whole-exome sequencing panel that analyzes tumor DNA alongside a normal sample and a whole-RNA transcriptome. The new CLIA/CAP-validated assay gives researchers and clinicians a broad view of potential tumor mutations and treatment pathways, Tempus said. 

Feb 21, 2018

Optra Health OptraGuru 'Digital Genetic Assistant'

Optra Health has introduced OptraGuru, an Amazon Alexa-compatible "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data. Meant to provide context to consumer genetic tests like those from Ancestry.com and 23andMe, OptraGuru puts the Alexa personal digital assistant on the front end of Optra Health's iPhronesis machine-learning platform to help patients, genetic counselors, and bioinformaticians make sense of genetic test results in a conversational manner.

Pages

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.